Myomo, Inc.

NYSE American MYO

Myomo, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024: -86.30%

Myomo, Inc. Return on Equity (ROE) is -86.30% for the Trailing 12 Months (TTM) ending September 30, 2024, a 1.58% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Myomo, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -87.68%, a 9.79% change year over year.
Myomo, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -97.20%, a -42.07% change year over year.
Myomo, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -68.42%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NYSE American: MYO

Myomo, Inc.

CEO	Mr. Paul R. Gudonis
IPO Date	June 12, 2017
Location	United States
Headquarters	137 Portland Street
Employees	101
Sector	Technology
Industries Robotics Medical Instruments

Description

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years